查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1247441

2023-2030 年全球免疫组织化学市场

Global Immunohistochemistry Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概览

预计到 2022 年，全球免疫组织化学市场规模将达到 23.0279 亿美元，到 2030 年将达到 42.4065 亿美元，预测期内（2023-2030 年）的复合年增长率为 8.1%。

抗体用于在称为免疫组织化学 (IHC) 的过程中识别组织片段（例如，肝臟、胰腺、心臟）内细胞中的蛋白质（抗原）。 当组织样本到达实验室进行疾病检测时，一些特征很难识别。 不同的疾病和疾病亚型表现不同，可能需要不同的治疗，即使它们在显微镜下看起来可能包含相同大小和形状的细胞。 区分这些细胞的最有效方法是寻找充当细胞标记的特定分子。

市场动态

推动全球免疫组织化学市场的主要因素是癌症发病率和患病率的增加、IHC 检测的报销潜力以及 IHC 技术进步带来的市场扩张。

癌症发病率和患病率的上升预计将推动市场的增长。

癌症的日益流行以及免疫组织化学在诊断感染、心血管疾病和其他疾病方面的流行都与这个市场的相当大的份额有关。 根据世界卫生组织 2022，癌症是一个广义术语，指的是可以影响身体任何部位的任何疾病。 使用的其他术语包括恶性肿瘤和赘生物。 到 2020 年，癌症将成为全球第一大死因，估计死亡人数将达到 1000 万人，即每 6 人中就有 1 人死亡。

典型的癌症包括乳腺癌、肺癌、结肠癌、直肠癌和前列腺癌。 大约三分之一的癌症相关死亡是由吸烟、高体重指数、饮酒、饮食中水果和蔬菜含量低以及缺乏锻炼引起的。

根据美国国立卫生研究院的数据，到 2020 年，估计美国将诊断出 1,806,590 例新癌症病例，606,520 人将死于该病。 最常见的癌症是乳腺癌、肺癌和支气管癌、前列腺癌、结肠癌和直肠癌、皮肤黑色素瘤、膀胱癌、非霍奇金淋巴瘤、肾臟和肾盂癌、子宫内膜癌、白血病、胰腺癌、甲状腺癌和肝癌（按 2020 年新增病例估计数降序排列）。 这些癌症疾病增加了对免疫化学工具的需求。

熟练病理学家的短缺预计会阻碍市场增长。

然而，缺乏训练有素的病理学家是市场扩张的製约因素。 病理学家使用自动化 IHC 平台对石蜡切片进行免疫组织化学 (IHC) 染色，应用适当的抗原修復技术，并解决设备损坏和染色效果差的问题。 如果没有病理学家，这是不可能的。 未经培训的技术人员是市场的障碍。

COVID-19 影响分析

很明显，SARS-CoV-2 的爆发可能是市场扩张的机会。 许多学术机构和生物製药公司正在努力将免疫荧光分析转化为有用的诊断工具。 COVID-19 流行病给全球供应网络造成了重大障碍。 许多全国性的封锁仍在继续，扰乱或暂时中断了原材料和成品的流动，影响了製造过程。

然而，免疫组织化学和原位杂交方法已经能够在福尔马林固定石蜡包埋 (FFPE) 标本中检测 SARS-CoV 和 SARS-CoV-2 病毒产物，该标本将于 2020 年发表。根据 12 月自然杂誌的一期，在未来将具有不可估量的价值。 在动物模型中研究冠状病毒病原体和治疗研究可以利用这些不同的方法进行病毒检测和材料合成。

此外，COVID-19 大流行影响了免疫组织化学试剂盒和试剂的可用性，我们预测未来几年用于 COVID-19 研究和诊断的需求量很大。事实一直如此。

内容

第 1 章研究方法和范围

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

第四章市场动态

  • 市场影响因素
    • 司机
      • 癌症发病率和患病率增加
      • IHC 测试报销的可能性
    • 阻止因素：
      • 熟练病理学家的短缺预计会阻碍市场增长
    • 商机
    • 影响分析

第五章行业分析

  • 波特的五力分析
  • 供应链分析
  • 价格分析
  • 监管分析

第 6 章 COVID-19 分析

  • 市场上 COVID-19 的分析
    • 在 COVID-19 市场情景之前
    • 当前的 COVID-19 市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格和动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 结论

第 7 章副产品

  • 抗体
    • 试剂
      • 组织染色
      • 封闭血清/试剂
      • 固定化试剂
      • 显色底物
      • 蛋白□
      • 有机溶剂
      • 稀释剂
      • 其他
    • 设备
      • 载玻片染色系统
      • 载玻片扫描仪
      • 组织处理系统
      • 其他
    • 工具包
      • 动物 IHC 试剂盒
      • 人类 IHC 试剂盒

第八章应用

  • 诊断
  • 药物测试
  • 法医申请
  • 其他

第 9 章最终用户

  • 医院
  • 诊断实验室
  • 学术和研究机构等
  • 其他

第10章按地区

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第11章竞争格局

  • 主要发展和战略
  • 公司股票分析
  • 产品基准
  • 知名大公司名单

第12章公司简介

  • 丹纳赫公司
    • 公司简介
    • 产品组合和说明
    • 主要亮点
    • 财务摘要
  • F. Hoffmann-La Roche Ag.
  • BD
  • Agilent Technologies, Inc.
  • Merck Kgaa
  • Bio-Rad Laboratories, Inc.
  • BioGenex
  • Abcam Plc
  • Candor Bioscience Gmbh
  • PerkinElmer, Inc.

第13章 DataM

简介目录
Product Code: PH3182

Market Overview

The global Immunohistochemistry market size was valued at US$ 2,302.79 million in 2022 and is estimated to reach US$ 4,240.65 million by 2030, growing at a CAGR of 8.1% during the forecast period (2023-2030).

Antibodies are employed in the process known as immunohistochemistry (IHC) to recognize proteins (antigens) in cells within a tissue segment (for instance, liver, pancreas or heart). Several characteristics are challenging to ascertain when a tissue sample is delivered to a lab for disease testing. Even if they may appear to contain identical cells in size or shape under a microscope, various diseases or disease subtypes may behave differently and call for different treatments. The most effective way to distinguish between these cells is to look for particular molecules that act as markers on them.

Market Dynamics

The major factors driving the global Immunohistochemistry market the market will expand as the growing incidence and prevalence of Cancer, availability of reimbursements for IHC tests and technological advancements in IHC.

Growing incidence and prevalence of Cancer are expected to drive the market's growth.

The growing prevalence of Cancer and the widespread use of immunohistochemistry in diagnosing infectious diseases, cardiovascular disorders, and other diseases are both associated with a substantial share of this market. According to World Health Organization 2022, Cancer is a broad term that refers to any disease that can affect any body part. Other terms used include malignant tumors and neoplasms. Cancer will be the leading cause of mortality worldwide in 2020, with an estimated 10 million deaths, or approximately one in every six.

The most common forms of Cancer include breast, lung, colon, rectum, and prostate. About one-third of cancer-related deaths are caused by smoking, high body mass index, consuming alcohol, eating few fruits and vegetables, and not exercising.

And according to the National Institutes of Health, in 2020, an estimated 1,806,590 new cases of Cancer will be diagnosed in the United States, and 606,520 people will die from the disease. The most common cancers (listed in descending order according to estimated new cases in 2020) are breast cancer, lung and bronchus Cancer, prostate cancer, colon and rectum cancer, melanoma of the skin, bladder cancer, non-Hodgkin lymphoma, kidney and renal pelvis cancer, endometrial Cancer, leukemia, pancreatic Cancer, thyroid cancer, and liver cancer. These conditions of cancer disorders increase the demand for immunochemistry tools.

Lack of skilled pathologists is expected to hamper the market's growth.

However, the market expansion is constrained by the absence of well-trained pathologists. The pathologist uses an automated IHC platform to carry out immunohistochemistry (IHC) stains on paraffin sections, applies the proper antigen retrieval methods, and resolves problems with broken equipment and subpar stains. And without the pathologist, it would not have been possible; untrained technicians are a hindrance to the market.

COVID-19 Impact Analysis

The SARS-CoV-2 outbreak became apparent as a potential window of opportunity for market expansion. Numerous academic institutions and biopharmaceutical businesses are examining the immunofluorescence assay to make it a useful diagnostic tool. The COVID-19 epidemic has caused significant barriers to global supply networks. Numerous nationwide lockdowns continue to impede or even temporarily block the flow of raw materials and completed goods, impacting the manufacturing process.

However, immunohistochemistry and in situ hybridization methods enable the detection of SARS-CoV and SARS-CoV-2 viral products in formalin-fixed paraffin-embedded (FFPE) specimens will be immensely valuable in the future, according to the Nature magazine, December 2020. Studies of coronavirus pathogenesis and therapeutic research in animal models can use these varied methods for virus detection and material synthesis.

Furthermore, the COVID-19 pandemic affected the availability of immunohistochemistry kits and reagents, yet, their use in COVID-19 research and diagnosis is predicted to enhance its demand in the coming years.

Segment Analysis

The diagnostics segment is expected to grow at the fastest CAGR during the forecast period (2023-2030)

The application segment is the highest market holder in the global immunohistochemistry market. Numerous market players' launches of new products, viral outbreaks, the prevalence of chronic diseases around the world, an increase in point-of-care diagnostics, and quickly advancing technology are major drivers of the segment's growth. The industry and academia continue to find the field appealing despite its rapid evolution. The development and subsequent administration of tailored medication using diagnostic techniques are projected to accelerate market expansion.

In addition, several market players engage in strategic initiatives. For instance, in January 2021, Diaceutics PLC, a company that offers diagnostic tracking, laboratory mapping, testing, and other services, announced a strategic partnership with Canadian Pathology Quality Assurance, a non-profit organization, to advance the development of Neurotrophic Tropomyosin Receptor Kinase (NTRK) IHC proficiency testing. And in June 2021, Amoy Diagnostics Co. Ltd., Riken Genesis Co. Ltd., and Precision Medicine Asia Co. Ltd. released the AmoyDx Pan Lung Cancer PCR Panel. The Ministry of Health, Labour, and Welfare (MHLW) has given the panel the go-ahead for marketing and production in Japan.

Geographical Analysis

North America holds the largest market share in the global Immunohistochemistry market.

North America dominates the global Immunohistochemistry market primarily due to factors like the presence of major companies, the high prevalence of Cancer and other chronic diseases in the area, and the well-established healthcare infrastructure are only a few of the major factors responsible for the market's growth. The existence of significant market participants, the ease with which IHC solutions are accessible, the increased use of technologically advanced IHC instruments, and the arrival of newer IHC solutions all contribute to the market expansion in the North American region.

For instance, in March 2022, Boston Cell Standards, a company dedicated to ensuring that cancer patients receive accurate diagnosis and treatment, announced that it launched the Consortium for Analytic Standardization in Immunohistochemistry (CASI). The new organization is led by an international panel of pathologists and scientists dedicated to improving patient immunohistochemistry (IHC) test accuracy and reproducibility. And in June 2021, PathAI, a U.S.-based provider of AI-powered technology for pathological applications, presented a machine learning-based quality control tool developed for HER2 testing in breast cancer in June 2021 at the American society of clinical oncology virtual scientific program 2021.

Competitive Landscape

The Immunohistochemistry market is moderately competitive with local and global companies' presence. Danaher Corporation, F. Hoffmann-La Roche Ag., BD, Agilent Technologies, Inc., Merck Kgaa, Bio-Rad Laboratories, Inc., BioGenex, Abcam Plc, Candor Bioscience Gmbh, PerkinElmer, Inc. and more. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the market's growth. For instance, in December 2021, according to BioGenex, a company that develops, produces, and distributes molecular pathology systems for tumor diagnosis, prognosis, precision medicine, and life science research, three new primary immunohistochemistry (IHC) antibodies for cancer diagnosis have been published. These are CD56, CD163, and CD8A, respectively.

BioGenex.

Overview: BioGenex creates, develops, and sells molecular pathology systems for life science research, precision medicine, and tumor detection and prognosis. Pathology is being revolutionized by BioGenex's market-leading next-generation cytogenetic FISH workflow solution and miRNA system for the characterisation of Cancer of Unknown Primary (CUP) and undifferentiated tumors. The most cutting-edge systems are proprietary fully automated molecular pathology workstations from BioGenex..

Product Portfolio:

IHC Detection Kits: Immunohistochemistry (IHC) Detection Systems are specially designed for the chromogenic detection of antigen-antibody binding reactions with primary antibodies of various sources (mouse or rabbit, IgG or IgM).

The global Immunohistochemistry market report would provide access to approx.: 45+market data table, 40+figures and 200 (approximate) pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Growing incidence and prevalence of Cancer.
      • 4.1.1.2. Availability of reimbursements for IHC tests.
    • 4.1.2. Restraints:
      • 4.1.2.1. Lack of skilled pathologist is expected to hamper the market's growth.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1 Porter's Five Forces Analysis
  • 5.2 Supply Chain Analysis
  • 5.3 Pricing Analysis
  • 5.4 Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Product

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 7.1.2. Market Attractiveness Index, By Product
  • 7.2. Antibodies
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis US$ Million, 2021-2030 and Y-o-Y Growth Analysis (%), 2022-2030
    • 7.2.3. Reagents
      • 7.2.3.1. Histological Stains
      • 7.2.3.2. Blocking Sera and Reagents
      • 7.2.3.3. Fixation Reagents
      • 7.2.3.4. Chromogenic Substrates
      • 7.2.3.5. Proteolytic Enzymes
      • 7.2.3.6. Organic Solvents
      • 7.2.3.7. Diluents
      • 7.2.3.8. Other
    • 7.2.4. Equipment
      • 7.2.4.1. Slide Staining Systems
      • 7.2.4.2. Slide Scanners
      • 7.2.4.3. Tissue Processing Systems
      • 7.2.4.4. Other
    • 7.2.5. Kits
      • 7.2.5.1. Animal IHC Kits
      • 7.2.5.2. Human IHC Kits

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Diagnostics
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis US$ Million, 2021-2030 and Y-o-Y Growth Analysis (%), 2022-2030
  • 8.3. Drug Testing
  • 8.4. Forensic Application
  • 8.5. Others

9. By End User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 9.1.2. Market Attractiveness Index, By End User
  • 9.2. Hospitals
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis US$ Million, 2021-2030 and Y-o-Y Growth Analysis (%), 2022-2030
  • 9.3. Diagnostic Laboratories
  • 9.4. Academic & Research Institutes
  • 9.5. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size AnalysisUS$ Million, 2021-2030 and Y-o-Y Growth Analysis (%), 2022-2030, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Products Benchmarking
  • 11.4. List of Key Companies to Watch

12. Company Profiles

  • 12.1. Danaher Corporation
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. F. Hoffmann-La Roche Ag.
  • 12.3. BD
  • 12.4. Agilent Technologies, Inc.
  • 12.5. Merck Kgaa
  • 12.6. Bio-Rad Laboratories, Inc.
  • 12.7. BioGenex
  • 12.8. Abcam Plc
  • 12.9. Candor Bioscience Gmbh
  • 12.10. PerkinElmer, Inc.

LIST NOT EXHAUSTIVE

13. Global Immunohistochemistry Market - DataM

  • 13.1. Appendix
  • 13.2. About Us and Application
  • 13.3. Contact Us